Cargando…
The impact of upper motor neuron involvement on clinical features, disease progression and prognosis in amyotrophic lateral sclerosis
OBJECTIVES: In amyotrophic lateral sclerosis (ALS) both upper (UMNs) and lower motor neurons (LMNs) are involved in the process of neurodegeneration, accounting for the great disease heterogeneity. We evaluated the associations of the burden of UMN impairment, assessed through the Penn Upper Motor N...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562695/ https://www.ncbi.nlm.nih.gov/pubmed/37822527 http://dx.doi.org/10.3389/fneur.2023.1249429 |
_version_ | 1785118184981921792 |
---|---|
author | Colombo, Eleonora Gentile, Francesco Maranzano, Alessio Doretti, Alberto Verde, Federico Olivero, Marco Gagliardi, Delia Faré, Matteo Meneri, Megi Poletti, Barbara Maderna, Luca Corti, Stefania Corbo, Massimo Morelli, Claudia Silani, Vincenzo Ticozzi, Nicola |
author_facet | Colombo, Eleonora Gentile, Francesco Maranzano, Alessio Doretti, Alberto Verde, Federico Olivero, Marco Gagliardi, Delia Faré, Matteo Meneri, Megi Poletti, Barbara Maderna, Luca Corti, Stefania Corbo, Massimo Morelli, Claudia Silani, Vincenzo Ticozzi, Nicola |
author_sort | Colombo, Eleonora |
collection | PubMed |
description | OBJECTIVES: In amyotrophic lateral sclerosis (ALS) both upper (UMNs) and lower motor neurons (LMNs) are involved in the process of neurodegeneration, accounting for the great disease heterogeneity. We evaluated the associations of the burden of UMN impairment, assessed through the Penn Upper Motor Neuron Score (PUMNS), with demographic and clinical features of ALS patients to define the independent role of UMN involvement in generating disease heterogeneity, predicting disease progression and prognosis. METHODS: We collected the following clinical parameters on a cohort of 875 ALS patients: age and site of onset, survival, MRC scale, lower motor neuron score (LMNS), PUMNS, ALSFRS-R, change in ALSFRS-R over time (DFS), MITOS and King’s staging systems (KSS). Transcranial magnetic stimulation was performed on a subgroup of patients and central motor conduction time (CMCT) and cortical silent period (CSP) were calculated. RESULTS: We observed that patients with an earlier age at onset and bulbar onset had higher PUMNS values. Higher values were also associated to lower ALSFRS-R and to higher DFS scores, as well as to higher MITOS and KSS, indicating that a greater UMN burden correlates with disease severity. Conversely, we did not appreciate any association between UMN involvement and survival or markers of LMN impairment. Moreover, PUMNS values showed a positive association with CMCT and a negative one with CSP values. INTERPRETATION: Our results suggest that the burden of UMN pathology, assessed through PUMNS, has an important independent role in defining clinical characteristics, functional disability, disease progression and prognosis in ALS patients. We also support the role of TMS in defining severity of UMN involvement. |
format | Online Article Text |
id | pubmed-10562695 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105626952023-10-11 The impact of upper motor neuron involvement on clinical features, disease progression and prognosis in amyotrophic lateral sclerosis Colombo, Eleonora Gentile, Francesco Maranzano, Alessio Doretti, Alberto Verde, Federico Olivero, Marco Gagliardi, Delia Faré, Matteo Meneri, Megi Poletti, Barbara Maderna, Luca Corti, Stefania Corbo, Massimo Morelli, Claudia Silani, Vincenzo Ticozzi, Nicola Front Neurol Neurology OBJECTIVES: In amyotrophic lateral sclerosis (ALS) both upper (UMNs) and lower motor neurons (LMNs) are involved in the process of neurodegeneration, accounting for the great disease heterogeneity. We evaluated the associations of the burden of UMN impairment, assessed through the Penn Upper Motor Neuron Score (PUMNS), with demographic and clinical features of ALS patients to define the independent role of UMN involvement in generating disease heterogeneity, predicting disease progression and prognosis. METHODS: We collected the following clinical parameters on a cohort of 875 ALS patients: age and site of onset, survival, MRC scale, lower motor neuron score (LMNS), PUMNS, ALSFRS-R, change in ALSFRS-R over time (DFS), MITOS and King’s staging systems (KSS). Transcranial magnetic stimulation was performed on a subgroup of patients and central motor conduction time (CMCT) and cortical silent period (CSP) were calculated. RESULTS: We observed that patients with an earlier age at onset and bulbar onset had higher PUMNS values. Higher values were also associated to lower ALSFRS-R and to higher DFS scores, as well as to higher MITOS and KSS, indicating that a greater UMN burden correlates with disease severity. Conversely, we did not appreciate any association between UMN involvement and survival or markers of LMN impairment. Moreover, PUMNS values showed a positive association with CMCT and a negative one with CSP values. INTERPRETATION: Our results suggest that the burden of UMN pathology, assessed through PUMNS, has an important independent role in defining clinical characteristics, functional disability, disease progression and prognosis in ALS patients. We also support the role of TMS in defining severity of UMN involvement. Frontiers Media S.A. 2023-09-26 /pmc/articles/PMC10562695/ /pubmed/37822527 http://dx.doi.org/10.3389/fneur.2023.1249429 Text en Copyright © 2023 Colombo, Gentile, Maranzano, Doretti, Verde, Olivero, Gagliardi, Faré, Meneri, Poletti, Maderna, Corti, Corbo, Morelli, Silani and Ticozzi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Colombo, Eleonora Gentile, Francesco Maranzano, Alessio Doretti, Alberto Verde, Federico Olivero, Marco Gagliardi, Delia Faré, Matteo Meneri, Megi Poletti, Barbara Maderna, Luca Corti, Stefania Corbo, Massimo Morelli, Claudia Silani, Vincenzo Ticozzi, Nicola The impact of upper motor neuron involvement on clinical features, disease progression and prognosis in amyotrophic lateral sclerosis |
title | The impact of upper motor neuron involvement on clinical features, disease progression and prognosis in amyotrophic lateral sclerosis |
title_full | The impact of upper motor neuron involvement on clinical features, disease progression and prognosis in amyotrophic lateral sclerosis |
title_fullStr | The impact of upper motor neuron involvement on clinical features, disease progression and prognosis in amyotrophic lateral sclerosis |
title_full_unstemmed | The impact of upper motor neuron involvement on clinical features, disease progression and prognosis in amyotrophic lateral sclerosis |
title_short | The impact of upper motor neuron involvement on clinical features, disease progression and prognosis in amyotrophic lateral sclerosis |
title_sort | impact of upper motor neuron involvement on clinical features, disease progression and prognosis in amyotrophic lateral sclerosis |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562695/ https://www.ncbi.nlm.nih.gov/pubmed/37822527 http://dx.doi.org/10.3389/fneur.2023.1249429 |
work_keys_str_mv | AT colomboeleonora theimpactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT gentilefrancesco theimpactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT maranzanoalessio theimpactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT dorettialberto theimpactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT verdefederico theimpactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT oliveromarco theimpactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT gagliardidelia theimpactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT farematteo theimpactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT menerimegi theimpactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT polettibarbara theimpactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT madernaluca theimpactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT cortistefania theimpactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT corbomassimo theimpactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT morelliclaudia theimpactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT silanivincenzo theimpactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT ticozzinicola theimpactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT colomboeleonora impactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT gentilefrancesco impactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT maranzanoalessio impactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT dorettialberto impactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT verdefederico impactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT oliveromarco impactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT gagliardidelia impactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT farematteo impactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT menerimegi impactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT polettibarbara impactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT madernaluca impactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT cortistefania impactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT corbomassimo impactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT morelliclaudia impactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT silanivincenzo impactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis AT ticozzinicola impactofuppermotorneuroninvolvementonclinicalfeaturesdiseaseprogressionandprognosisinamyotrophiclateralsclerosis |